DailyStocks Stock Article Search

https://www.zacks.com/stock/news/2205766/agios-agio-up-5-on-upbeat-data-from-thalassemia-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2205766 Jan 04, 2024 - Data from a late-stage study shows that non-transfusion-dependent thalassemia patients who received Agios' (AGIO) mitapivat demonstrated a statistically significant increase in hemoglobin response. 0

https://www.zacks.com/stock/news/2205605/biotech-stock-roundup-vygr-gains-from-nvs-deal-agio-up-on-study-data-more?cid=CS-ZC-FT-analyst_blog|stock_roundup-2205605 Jan 04, 2024 - Collaboration news from Voyager (VYGR) and study updates from Agios (AGIO) are the key highlights this week. 0

https://www.zacks.com/stock/news/2218010/amgen-amgn-earnings-expected-to-grow-what-to-know-ahead-of-next-week-s-release?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_9-2218010 Jan 30, 2024 - Amgen (AMGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. 0

https://www.zacks.com/stock/news/2218934/bristol-myers-bmy-sblas-for-breyanzi-get-fda-priority-tag?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2218934 Jan 31, 2024 - Bristol Myers' (BMY) two sBLAs for Breyanzi in relapsed/refractory follicular lymphoma and relapsed/refractory mantle cell lymphoma receive FDA acceptance and priority review. 0

https://www.zacks.com/stock/news/2220250/compared-to-estimates-bristol-myers-bmy-q4-earnings-a-look-at-key-metrics?cid=CS-ZC-FT-fundamental_analysis|nfm-2220250 Feb 02, 2024 - While the top- and bottom-line numbers for Bristol Myers (BMY) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. 0

https://www.zacks.com/stock/news/2221922/bristol-myers-bmy-tsvt-car-t-cell-therapy-to-face-fda-s-odac?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2221922 Feb 06, 2024 - Bristol Myers (BMY) and its partner TSVT announce that the FDA's ODAC will meet in March to review data supporting the label expansion for CAR T-cell therapy. 0

https://www.zacks.com/stock/news/2241446/bristol-myers-bmy-gets-fda-nod-for-breyanzi-s-label-expansion?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2241446 Mar 15, 2024 - Bristol Myers (BMY) obtains FDA approval for the label expansion of CAR T cell therapy, Breyanzi, for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). 0

https://www.zacks.com/stock/news/2244465/bristol-myers-squibb-bmy-stock-declines-while-market-improves-some-information-for-investors?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v1-2244465 Mar 21, 2024 - In the latest trading session, Bristol Myers Squibb (BMY) closed at $51.59, marking a -0.56% move from the previous day. 0

https://www.zacks.com/stock/news/2244198/biotech-stock-roundup-gern-crnx-gain-on-updates-bmy-s-car-t-cell-therapy-news-more?cid=CS-ZC-FT-analyst_blog|stock_roundup-2244198 Mar 21, 2024 - Geron Corporation (GERN) and Crinetics Pharmaceuticals (CRNX) gain on positive regulatory and study updates. 0

https://www.zacks.com/stock/news/2252179/bristol-myers-bmy-gets-fda-nod-for-label-expansion-of-abecma?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2252179 Apr 08, 2024 - Bristol Myers (BMY) wins FDA approval for CAR T cell immunotherapy, Abecma, in earlier lines of treatment for patients with relapsed or refractory multiple myeloma. 0